Long-acting insulin or insulin analogue conjugate
The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.
1. A long-acting conjugate of the following Formula 1:
X-La-F1:Y-La-F2, Formula 1
wherein, in the above Formula,
X is a wild-type insulin A-chain or analogue thereof;
L is a linker;
a is 0 or a natural number, with the proviso that each L is independent from each other when a is 2 or greater;
: is a chemical bond between F1 and F2;
Y is a wild-type insulin B-chain or analogue thereof; and
F1 and F2 each comprise a single chain polypeptide of immunoglobulin constant region and have an FcRn-binding site,
wherein the chemical bond between F1 and F2 is a disulfide bond, and the long-acting conjugate forms a heterodimer via the disulfide bond, and
wherein F1 is conjugated to carboxyl end of X via the linker L, and F2 is conjugated to carboxyl end of Y via the linker L.
2. The conjugate of claim 1 , wherein each of the immunoglobulin constant region of F1 and F2 consists of 1 to 4 domains selected from the group consisting of CH1, CH2, CH3, and CH4 domains.
3. The conjugate of claim 2 , wherein the immunoglobulin constant region is IgG.
4. The conjugate of claim 1 , wherein each of the immunoglobulin constant region of F1 and F2 consists of a hinge region and 1 to 4 domains selected from the group consisting of CH1, CH2, CH3, and CH4 domains.
5. The conjugate of claim 1 , wherein:
F1 comprises a hinge region, CH2 region, and CH3 region of IgG1, in which serine, which is the amino acid at the 24 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with histidine, and phenylalanine, which is the amino acid at the 65 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with alanine; and
F2 comprises a hinge region, CH2 region, and CH3 region of IgG1, in which tyrosine, which is the amino acid at the 9 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with threonine, and threonine, which is the amino acid at the 54 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with phenylalanine.
6. The conjugate of claim 1 , wherein F1 and F2 are non-wild-type immunoglobulin regions with amino acid substitution(s), and wherein amino acid substitution(s) in the F2 and amino acid substitution(s) in the F1 are different from each other.
7. The conjugate of claim 1 , wherein the linker L comprises a peptide or polyethylene glycol.
8. The conjugate of claim 1 , wherein the insulin B-chain analogue has one or more amino acid substitutions at position(s) selected from the group consisting of amino acids at the 8 th , 10 th , 12 th , 16 th , 23 rd , 24 th , 25 th , 26 th , 27 th , 28 th , 29 th , and 30 th positions of the wild-type insulin B-chain,
wherein the wild-type insulin B-chain consists of the amino acid sequence of SEQ ID NO:2.
9. The conjugate of claim 1 , wherein the insulin A-chain analogue has one or more amino acid substitutions at position(s) selected from the group consisting of amino acids at 1 st , 2 nd , 5 th , 14 th , 19 th , and 21 st positions of the wild-type insulin A-chain,
wherein the wild-type insulin A-chain consists of the amino acid sequence of SEQ ID NO:1.
10. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.
11. A method for treating diabetes, comprising administering an effective amount of the conjugate of claim 1 to a subject in need thereof.
12. A method of preparing the conjugate of claim 1 , comprising
(a) preparing A-chain linked material in the form of [X-La-F1] and B-chain linked material in the form of [Y-La-F1];
(b) preparing a vector comprising the linked materials; and
(c) expressing the vector in a host cell to produce the conjugate,
wherein,
X is a wild-type insulin A-chain or analogue thereof;
L is a linker;
a is 0 or a natural number, with the proviso that each L is independent from each other when a is 2 or greater;
Y is a wild-type insulin B-chain or analogue thereof; and
F1 and F2 each comprise a single chain polypeptide of immunoglobulin constant region and have an FcRn-binding site,
wherein the chemical bond between F1 and F2 is a disulfide bond, and the long-acting conjugate forms a heterodimer via the disulfide bond, and
wherein F1 is conjugated to carboxyl end of X via the linker L, and F2 is conjugated to carboxyl end of Y via the linker L.
13. The method of claim 12 , wherein the (c) step comprises a refolding process of the linked materials.
14. The method of claim 13 , wherein the method is characterized in that the method is devoid of the removal of C-peptide after the refolding process.
15. The method of claim 12 , wherein:
F1 comprises a hinge region, CH2 region, and CH3 region of IgG1, in which serine, which is the amino acid at the 24 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with histidine, and phenylalanine, which is the amino acid at the 65 th position of the wild-type CH3 region, is substituted with alanine; and
F2 comprises a hinge region, CH2 region, and CH3 region of IgG1, in which tyrosine, which is the amino acid at the 9 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with threonine, and threonine, which is the amino acid at the 54 th position of the wild-type CH3 region of SEQ ID NO: 24, is substituted with phenylalanine.